Breast Cancer Research and Treatment Highlights Development and Validation of BluePrint®

Irvine, California and Amsterdam (ots/PRNewswire) -

- Peer-Reviewed Article Notes That Multi-Gene Subtyping Profile
Provides Deeper Insight Into Breast Cancer

Agendia, an innovative molecular cancer diagnostics company, today
announced that a published report highlighting the development and
validation of its 80-gene BluePrint breast cancer profile was
published online in Breast Cancer Research and Treatment, a
peer-reviewed publication. BluePrint is a part of Agendia's
Symphony(TM) suite of breast cancer products, a comprehensive
collection of genetic assays that help address complex treatment
decisions for any type and stage of breast cancer. The article notes
that, when used in combination with Agendia's FDA-cleared
MammaPrint(R)recurrence test, BluePrint provides an additional level
of understanding for physicians, classifying breast cancer patients
into Basal-type, Luminal-type A and B, and HER2-type subgroups.
Recently, the expert panel at the 12th St. Gallen International
Breast Cancer Conference (2011) recommended specific treatments for
those particular breast cancer subtypes.

"This article illustrates the vital role of molecular subtyping in
the treatment decision process for breast cancer patients. The
combination of Symphony's MammaPrint and BluePrint micro-array assays
provides physicians with unprecedented insight into their patient's
tumor," said Dr. Bernhard Sixt, Agendia's CEO and co-founder. "From
just one biopsy sample, Agendia's Symphony suite of tests provides
clear insight into who to treat and how to treat them, helping to
identify the optimal treatment tailored to each patient's individual
needs and genetics."

The article describes molecular subtyping of breast cancer
patients as "...important for the proper selection of therapy, as
tumors with seemingly similar histopathological features can have
strikingly different clinical outcomes." Further, the use of
BluePrint may improve clinical management of breast cancer patients
by identifying those patients who are most likely to benefit from
either chemotherapy or endocrine therapy.

Recent studies have shown that the classification of breast cancer
into molecular subtypes is largely represented by the estrogen
receptor (ER), progesterone receptor (PR) and the HER2 status of the
tumor. Breast cancer can be classified into molecular subtypes by
simple hiererarchical clustering of breast tumors according to their
gene expression patterns.

About Agendia:

Agendia [http://www.agendia.com ] is a leading global commercial
molecular diagnostic company that develops and markets genomic-based
diagnostic products that improve the quality of life for cancer
patients and simplifies complex treatment decisions for their
physicians. Agendia's Symphony(TM) suite of breast cancer products is
based on the analysis of hundreds of genes in a patient's breast and
provides unprecedented biological insight to address complex
treatment decisions. Symphony includes MammaPrint, the first and only
FDA-cleared IVDMIA breast cancer recurrence assay, as well as
BluePrint, a molecular subtyping assay, TargetPrint(R), an ER/PR/HER2
expression assay, and TheraPrint(R), a therapy selection assay.
Together, these tests help physicians determine a patient's
individual risk for metastasis, which patients will benefit from
chemo or hormonal therapy, and which patients do not require these
treatments and can instead be treated with other less arduous and
costly methods.

In addition to the Symphony suite of tests, Agendia has a rich
pipeline of genomic products in development based on its world-class
genomic platform. The company also collaborates with pharmaceutical
companies to develop companion diagnostic tests in the area of
oncology and is a critical partner in the ISPY-2 and MINDACT trials.

Agendia was founded in 2003 as a spin-off of the Netherlands
Cancer Institute and is based in Irvine, California, United States,
and Amsterdam, the Netherlands. For more information, please visit
http://www.agendia.com.

Rückfragehinweis:
For further information, please contact: Ricochet Public
Relations, Valerie Carter, Tel: +1-202-316-0143, E-mail:
Agendia@ricochetpr.com

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | PRN

print